Quantumzyme Advances Sustainable Pharmaceutical Manufacturing with International Patent Publications
Quantumzyme's newly announced international patents for enzymatic ibuprofen synthesis represent a significant advancement in green pharmaceutical manufacturing that could reduce chemical waste and improve production efficiency.
Quantumzyme Corp. has announced details regarding the World Intellectual Property Organization publication of its international patent application covering modified polypeptides for enzymatic synthesis of ibuprofen, marking a strategic step in the company's sustainable pharmaceutical manufacturing initiatives. The patent publication, identified as WO 2025/093935 A1, complements the company's previously announced U.S. Patent Application Publication No. US 2025/0146029 A1, establishing comprehensive intellectual property protection for Quantumzyme's enzyme engineering platform across both domestic and international markets.
These patent publications strengthen Quantumzyme's position in the growing green chemistry sector and represent significant progress toward commercializing an enzymatic process for ibuprofen manufacturing. The patented biocatalytic method is designed to reduce chemical waste, eliminate harsh reagents, and enhance overall manufacturing efficiency compared to traditional chemical synthesis methods. This approach aligns with increasing industry demand for more sustainable pharmaceutical production processes that minimize environmental impact while maintaining cost-effectiveness.
According to CEO Naveen Kulkarni, the patent publications validate the strength of Quantumzyme's enzyme engineering technology and enhance the company's position for global partnerships focused on greener pharmaceutical manufacturing. The company can now advance into optimization and pilot-testing phases while engaging with potential partners interested in sustainable and scalable active pharmaceutical ingredient production. The technology builds on Quantumzyme's proprietary QZyme Workbench platform, which integrates quantum mechanics, molecular modeling, and AI-driven optimization to design next-generation biocatalysts.
Quantumzyme's broader growth strategy centers on expanding enzyme engineering capabilities, strengthening intellectual property portfolios, and advancing discussions with potential global partners. The company intends to continue laboratory optimization and scale-up validation of the enzymatic ibuprofen synthesis process while pursuing discussions with global pharmaceutical and contract manufacturing organizations regarding licensing or joint-development frameworks. Additional patent applications covering related enzymatic transformations and process improvements are also planned as part of the company's ongoing innovation efforts. For more information, visit https://www.quantumzymecorp.com and https://www.otcmarkets.com/stock/QTZM.